What inspired this wish list request?
Currently, JMP's (JMP Pro 19.0.0) built-in 4PL (Four Parameter Logistic) model uses an exponential function with base e, while our validated bioassay analysis software uses a 4PL model with base b = 2. Because of this difference, results from JMP cannot be directly compared with those generated by our validated workflow.
Our team relies on validated software to calculate relative potencies and perform bioassay analyses. However, every action in the validated software is recorded in an audit trail, making exploratory analyses time consuming. For example, when investigating whether removing a specific dilution point from bioassay improves suitability criteria such as equivalence, parallelism, or R^2, each modification requires documentation and justification.
JMP is an excellent environment for rapidly exploring data and understanding how changes affect assay performance. However, the inability to define a custom 4PL model using a different logarithmic base limits our ability to use JMP as a screening and exploratory tool while maintaining consistency with our validated calculations.
What is the improvement you would like to see?
I would like JMP to support user-defined 4PL models, allowing users to specify the exponential/logarithmic base used in the curve-fitting equation (e.g., base 2 instead of the current base e implementation).
In addition, it would be valuable if user-defined 4PL models could leverage the same bioassay functionality that is currently available for JMP's predefined models, including:
Relative potency calculations
Parallelism testing
Equivalence testing
Confidence interval estimation
Combined relative potency calculation using homogeneity or heterogeneity testing
Other bioassay suitability and comparability metrics
Ideally, users could define a custom model formula within the Bioassay platform or through a scripting interface (JSL) and then apply the standard bioassay analysis workflow to that model.
Example use case:
Fit a custom 4PL model with base 2.
Set and evaluate assay suitability criteria.
Remove or include selected dilution points.
Immediately observe the impact on relative potency estimates, confidence intervals, equivalence, parallelism, and goodness-of-fit metrics.
Use the results for exploratory assessment before executing the formal analysis in validated software.
Why is this idea important?
This idea could significantly improve JMP's value as a bioassay exploration and decision-support tool.
It would provide:
Consistency with validated workflows: Users could match the exact model specification used in validated software, increasing confidence when comparing results.
Faster exploratory analysis: Scientists could rapidly investigate data quality issues, outliers, and alternative fitting scenarios without the burden associated with validated systems.
Improved efficiency: Assessing the impact of data changes on relative potency, confidence intervals, equivalence, and parallelism could be performed in real time.
Greater flexibility: Organizations using custom or default assay models would be able to use JMP without needing to compromise on their established model specifications.
Adoption of JMP in regulated environments: JMP could serve as a powerful sandbox environment for evaluating assay behavior prior to formal analysis and reporting.
... View more